Autoimmune Diseases

Antibiotics Linked to Higher Risk of Inflammatory Bowel Disease

September 11, 2020

Higher cumulative exposure to systemic antibiotic therapy may be associated with a greater risk of new-onset inflammatory bowel disease.

Prevent Medication Errors in Autoimmune Disease

September 10, 2020

Pharmacists can play an important role in educating patients about autoimmune drugs to prevent medication errors.

Opicapone Can Help Treat Patients Experiencing “Off” Episodes With Parkinson Disease

August 21, 2020

Levodopa/carbidopa is currently the gold standard for controlling motor symptoms associated with Parkinson disease.

FDA OKs Ofatumumab for Treatment of Relapsing Multiple Sclerosis

August 20, 2020

Ofatumumab (Kesimpta; Novartis) is the first and only self-administered, targeted B-cell therapy for the treatment of relapsing multiple sclerosis.

FDA Approves Satralizumab-mwge for Treatment of Rare Autoimmune Disease

August 18, 2020

The therapy received fast track designation and was approved in just over 1 year.

Investigators Find COVID-19 Connection in Vasculitis

August 14, 2020

A Kawasaki-like inflammatory disease has affected children who have coronavirus disease 2019.

Investigational Long-Acting Injectable Cabotegravir Shows Superior Efficacy Over Daily Oral PrEP

July 13, 2020

The data from a new study has shown that investigational, long-acting injectable cabotegravir boasted a 66% higher efficacy than daily oral pills in preventing HIV-1.

Women With HIV and Persistent Depression May Experience Greater Risk for Heart Disease

July 03, 2020

A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress.

Studies Reveal Positive Results for Infliximab Biosimilar

June 18, 2020

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.

Prescription Fills Surge for Hydroxychloroquine, Chloroquine During Pandemic

June 04, 2020

A recent analysis showed a surge in prescription fills for hydroxychloroquine/chloroquine, likely due to off-label prescribing for coronavirus disease 2019. 

FDA Approves Ixekizumab for Non-radiographic Axial Spondyloarthritis

June 03, 2020

Ixekizumab (Taltz, Eli Lilly) is the first interleukin-17A antagonist to be approved for non-radiographic axial spondyloarthritis.

New Oral Treatment for Relapsing Forms of Multiple Sclerosis Now Available

June 03, 2020

Bristol Myers Squibb announced the commercial US launch of ozanimod (Zeposia) for the treatment of relapsing forms of multiple sclerosis.

Filgotinib Trial Shows Positive Results in Ulcerative Colitis

May 26, 2020

Filgotinib achieved all primary end points of the phase 2b/3 study in patients with moderate-to-severe ulcerative colitis.

FDA Approves Dupilumab for Atopic Dermatitis in Children

May 26, 2020

Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.

Phase 3 Study: Apremilast Shows Efficacy in Mild-to-Moderate Plaque Psoriasis

May 08, 2020

Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.

Rituximab Biosimilar Now Available in United States for Rheumatoid Arthritis

May 04, 2020

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

Early Treatment with Ocrelizumab Reduces Disability Risk by Nearly Half in Relapsing MS

April 28, 2020

Six-year data from the new analyses add evidence to the benefit-risk profile of ocrelizumab (Ocrevus, Genentech) for patients with multiple sclerosis. 

AGA Releases Expert Commentary for IBD Management During COVID-19

April 27, 2020

Depending on the situation, individuals with IBD who develop COVID-19 may want to alter their medication.

Long-Term Data Show Sustained Benefit of Siponimod for Secondary Progressive MS

April 22, 2020

Siponimod (Mayzent, Novartis) had a sustained effect on slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS), according to new long-term data from a phase 3 study.

FDA Accepts sBLA for Shorter Infusion Time with Ocrelizumab

April 20, 2020

Genentech is seeking approval for a 2-hour ocrelizumab (Ocrevus) infusion time in patients with relapsing or primary progressive multiple sclerosis.